Company Overview of Zepteon, Inc.
Zepteon, Inc. develops chromatography resins for separating antibodies with specific sugar structures (nonfucosylated) that are potent against diseases like cancer. It offers Glycap-3A, a resin to make a biosimilar antibody with a nonfucose level that matches that of the original drug. The company was founded in 2012 and is based in Boston, Massachusetts.
42 Chauncy Street
Boston, MA 02111
Founded in 2012
Key Executives for Zepteon, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Zepteon, Inc., please visit www.zepteon.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.